Employee-related Liabilities, Current of MADRIGAL PHARMACEUTICALS, INC. from 31 Dec 2011 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
- Summary
-
MADRIGAL PHARMACEUTICALS, INC. quarterly Employee-related Liabilities, Current in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
- MADRIGAL PHARMACEUTICALS, INC. Employee-related Liabilities, Current for the quarter ending 31 Dec 2025 was $69,211,000, a 102% increase year-over-year.
- Source SEC data
- View on sec.gov
Employee-related Liabilities, Current, Quarterly (USD)
Employee-related Liabilities, Current, YoY Quarterly Change (%)
MADRIGAL PHARMACEUTICALS, INC. Quarterly Employee-related Liabilities, Current (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $69,211,000 | +$35,002,000 | +102% | 31 Dec 2025 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2025 | $51,108,000 | +$21,424,000 | +72% | 30 Sep 2025 | 10-Q | 04 Nov 2025 | 2025 | Q3 |
| Q2 2025 | $27,691,000 | +$6,350,000 | +30% | 30 Jun 2025 | 10-Q | 05 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $18,272,000 | +$1,320,000 | +7.8% | 31 Mar 2025 | 10-Q | 01 May 2025 | 2025 | Q1 |
| Q4 2024 | $34,209,000 | +$17,179,000 | +101% | 31 Dec 2024 | 10-K | 19 Feb 2026 | 2025 | FY |
| Q3 2024 | $29,684,000 | 30 Sep 2024 | 10-Q | 31 Oct 2024 | 2024 | Q3 | ||
| Q2 2024 | $21,341,000 | 30 Jun 2024 | 10-Q | 07 Aug 2024 | 2024 | Q2 | ||
| Q1 2024 | $16,952,000 | 31 Mar 2024 | 10-Q | 07 May 2024 | 2024 | Q1 | ||
| Q4 2023 | $17,030,000 | +$2,166,000 | +15% | 31 Dec 2023 | 10-K | 26 Feb 2025 | 2024 | FY |
| Q4 2022 | $14,864,000 | 31 Dec 2022 | 10-K | 28 Feb 2024 | 2023 | FY | ||
| Q2 2016 | $714,000 | -$2,281,000 | -76% | 30 Jun 2016 | 10-Q | 20 Jul 2016 | 2016 | Q2 |
| Q1 2016 | $1,349,000 | -$1,256,000 | -48% | 31 Mar 2016 | 10-Q | 10 May 2016 | 2016 | Q1 |
| Q4 2015 | $3,072,000 | -$780,000 | -20% | 31 Dec 2015 | 10-Q | 20 Jul 2016 | 2016 | Q2 |
| Q3 2015 | $2,605,000 | -$171,000 | -6.2% | 30 Sep 2015 | 10-Q | 05 Nov 2015 | 2015 | Q3 |
| Q2 2015 | $2,995,000 | +$309,000 | +12% | 30 Jun 2015 | 10-Q | 06 Aug 2015 | 2015 | Q2 |
| Q1 2015 | $2,605,000 | +$443,000 | +20% | 31 Mar 2015 | 10-Q | 07 May 2015 | 2015 | Q1 |
| Q4 2014 | $3,852,000 | +$715,000 | +23% | 31 Dec 2014 | 10-K | 15 Mar 2016 | 2015 | FY |
| Q3 2014 | $2,776,000 | +$514,000 | +23% | 30 Sep 2014 | 10-Q | 06 Nov 2014 | 2014 | Q3 |
| Q2 2014 | $2,686,000 | +$987,000 | +58% | 30 Jun 2014 | 10-Q | 06 Aug 2014 | 2014 | Q2 |
| Q1 2014 | $2,162,000 | +$1,004,000 | +87% | 31 Mar 2014 | 10-Q | 08 May 2014 | 2014 | Q1 |
| Q4 2013 | $3,137,000 | -$135,000 | -4.1% | 31 Dec 2013 | 10-K | 12 Mar 2015 | 2014 | FY |
| Q3 2013 | $2,262,000 | +$283,000 | +14% | 30 Sep 2013 | 10-Q | 04 Nov 2013 | 2013 | Q3 |
| Q2 2013 | $1,699,000 | +$280,000 | +20% | 30 Jun 2013 | 10-Q | 01 Aug 2013 | 2013 | Q2 |
| Q1 2013 | $1,158,000 | 31 Mar 2013 | 10-Q | 30 Apr 2013 | 2013 | Q1 | ||
| Q4 2012 | $3,272,000 | +$358,000 | +12% | 31 Dec 2012 | 10-K | 11 Mar 2014 | 2013 | FY |
| Q3 2012 | $1,979,000 | 30 Sep 2012 | 10-Q | 06 Nov 2012 | 2012 | Q3 | ||
| Q2 2012 | $1,419,000 | 30 Jun 2012 | 10-Q | 02 Aug 2012 | 2012 | Q2 | ||
| Q4 2011 | $2,914,000 | 31 Dec 2011 | 10-K | 14 Mar 2013 | 2012 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.